BioNova Pharm is engaged in the development of innovative biopharmaceutical products aimed at addressing significant unmet medical needs, particularly in the fields of inflammatory and fibrotic diseases, as well as immuno-oncology. The company has established strategic partnerships with various organizations to enhance its product pipeline. Notably, BioNova collaborates with Kadmon to develop KD025, a treatment for chronic graft-versus-host disease (cGVHD), which has received Breakthrough Therapy Designation from the FDA. Additionally, BioNova has partnered with PharmaResources to discover small molecules targeting hematologic malignancies, and with Carna Biosciences to develop AS-1763, a next-generation Bruton's tyrosine kinase inhibitor for the Greater China market.

In its pursuit of advanced therapeutic solutions, BioNova also collaborates with Sutro Biopharma to develop STRO-001, an antibody-drug conjugate targeting CD74 for hematologic cancers. This partnership leverages Sutro's proprietary protein engineering platforms, which facilitate the rapid discovery and development of optimized drug candidates. Furthermore, BioNova's collaborations with industry leaders like WuXi STA and Insilico Medicine highlight its commitment to integrating cutting-edge technologies and methodologies in drug development, ensuring a robust approach to tackling complex medical challenges.

China

BioNova Pharmaceuticals Ltd is an innovative biotech company engaged primarily in the discovery, development and commercialization of breakthrough therapies for the treatment of diseases with high unmet medical need, with a focus on the Greater China market 

Our talent, scientific knowledge and research capabilities help us accelerate drug development in China and bring innovative medicines to the Chinese patients


Cancer

BioNova Pharm

Acute myeloid leukemia

Multiple myeloma

Non-Hodgkin lymphoma

BN301

Antibodies

Biologics

2889 Jinke Road, Chamtime Plaza, Building B, 9F,Suite 901 Shanghai 201203, China

Antibody Drug Conjugates

Immuno-Oncology

Small Molecule Pharmaceuticals

Therapeutic

BioNova Pharm

Company Details